Literature DB >> 33582171

Tackling cancer cell dormancy: Insights from immune models, and transplantation.

Alexandre Corthay1, Tibor Bakacs2, Govindarajan Thangavelu3, Colin C Anderson4.   

Abstract

Disseminated non-dividing (dormant) cancer cells as well as those in equilibrium with the immune response remain the major challenge for successful treatment of cancer. The equilibrium between disseminated dormant cancer cells and the immune system is reminiscent of states that can occur during infection or allogeneic tissue and cell transplantation. We discuss here the major competing models of how the immune system achieves a self nonself discrimination (pathogen/danger patterns, quorum, and coinhibition/tuning models), and suggest that taking advantage of a combination of the proposed mechanisms in each model may lead to increased efficacy in tackling cancer cell dormancy.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer dormancy; Coinhibitory; Hyperthermia; Immune tolerance; T cell activation

Mesh:

Year:  2021        PMID: 33582171     DOI: 10.1016/j.semcancer.2021.02.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  3 in total

1.  Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia.

Authors:  Ralf Kleef; Viktor Bacher; Robert Nagy; Peter Reisegger; Tibor Bakacs
Journal:  Cureus       Date:  2021-04-15

2.  Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.

Authors:  Wenhui Liu; Fang Ma; Bao Sun; Yiping Liu; Haoneng Tang; Jianquan Luo; Huiqing Chen; Zhiying Luo
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 3.  Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation.

Authors:  Chao Yang; Chan-Tat Ng; Dan Li; Lei Zhang
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.